Shares of biopharmaceutical company Soleno Therapeutics, Inc. (SLNO) were in the spotlight on Monday after the company ...

Soleno Therapeutics won approval for a drug that treats excessive hunger associated with a rare disease, and the biotech stock rocketed.

INDICATION VYKAT XR is indicated for the treatment of hyperphagia in adults and pediatric patients 4 years of age and older with Prader-Willi syndrome (PWS). Contraindications Use of VYKAT XR is ...

Soleno Therapeutics stock has surged over 1,500% since September 2023, driven by the progress and today's FDA approval of Vykat for Prader-Willi syndrome, despite initial clinical trial challenges.

(RTTNews) - Soleno Therapeutics, Inc. (SLNO), Monday said VYKAT XR which was approved by the Food and Drug Administration (FDA) on March 26 to treat hyperphagia in patients four years of age and ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Shares of Soleno Therapeutics, Inc. (NASDAQ:SLNO – Get Free Report) traded down 6.7% during mid-day trading on Tuesday following insider selling activity.The stock traded as low as $67.23 and ...

Soleno Therapeutics (SLNO) announced the U.S. commercial availability of VYKAT XR extended-release tablets, the company’s treatment for ...

REDWOOD CITY, Calif., April 14, 2025 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Soleno) (NASDAQ: SLNO), a biopharmaceutical company developing novel therapeutics for the treatment of rare ...